Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study.

摘要: ABSTRACT Purpose: We evaluated the efficacy and tolerability of pentosan polysulfate sodium (PPS) for treatment men with chronic pelvic pain syndrome (CPPS), National Institutes Health (NIH) category III. Materials Methods: In a 16-week double-blind study 100 clinical diagnosis CPPS were randomized to receive 300 mg PPS or placebo 3 times daily. Clinical Global Improvement (CGI) was primary outcome measure. Additional measures NIH-Chronic Prostatitis Symptom Index (CPSI), Subjective Assessment Severity assessment tools. Results: Significantly more patients receiving experienced moderate marked improvement based on CGI (18 37% vs 8 18%, p = 0.04). However, mean scores not significantly different between group (1.0) groups (1.0 0.6, 0.107). All NIH-CPSI domains suggested positive effect total difference approached statistical significance (−5.9 22% −3.2 12%, 0.068). The showed greater in quality life domain than (−2.0 −1.0 0.031). Of 67% 80% those completed study. Diarrhea, nausea headache most common adverse events. Conclusions: Pentosan (900 daily) likely provide relief symptoms.